Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
23 févr. 2021 08h00 HE
|
Rubius Therapeutics
Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021 Escalated the Dose in...
Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
18 févr. 2021 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
09 févr. 2021 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is using its platform to genetically engineer red blood...
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
03 févr. 2021 16h45 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference
11 janv. 2021 08h00 HE
|
Rubius Therapeutics
Initial Clinical Data Show RTX-240 Stimulates Innate and Adaptive Immunity (NK Cells and T Cells) Supporting Proof of Mechanism – Additional Results to be Presented in Early 2021 IND Cleared and...
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
04 janv. 2021 16h01 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
30 nov. 2020 16h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
10 nov. 2020 16h01 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
09 nov. 2020 08h05 HE
|
Rubius Therapeutics
Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial Dosed First Patient in RTX-240 Phase 1 Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Filed...
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
09 nov. 2020 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...